SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "Company") (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $42.00 in cash for each share of Albireo common stock owned, plus one contingent value right ("CVR") per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR.